BACKGROUND: @entity1073 ( @entity1073 ) is associated with the worst prognosis among low-grade @entity1892 . While cutaneous involvement by nodal or systemic @entity1073 is uncommon, its differentiation from primary @entity1892 ( @entity1892 ) or cutaneous involvement by other extra-cutaneous BCL is challenging as neither histomorphology nor immunophenotype can be absolutely specific. We analyzed the diagnostic utility of @entity57431 immunohistochemistry in differentiating secondary cutaneous @entity1073 from other low-grade @entity1892 . METHODS: Immunohistochemical staining with anti- @entity57431 antibody was performed on 8 cases of secondary cutaneous @entity1073 , 16 secondary cutaneous CLL, 20 primary cutaneous MZL, 12 cutaneous FCL (6 primary, 6 secondary), 7 primary cutaneous DLBCL, leg type, 5 systemic DLBCL and 3 B-ALL. @entity57431 and @entity4910 staining were compared in secondary cutaneous @entity1073 . RESULTS: Nuclear @entity57431 staining was seen in seven of eight cases (88%) of secondary cutaneous @entity1073 , including a case with minimal @entity4910 expression. All other @entity1892 lacked detectable nuclear @entity57431 expression. The sensitivity and specificity for @entity57431 in @entity1073 were 87.5 and 100%, respectively. Both the sensitivity and specificity for combined @entity57431 and @entity4910 immunohistochemistry were 100%. CONCLUSION: @entity57431 immunohistochemistry could be a useful adjunct in distinguishing secondary cutaneous @entity1073 from other @entity1892 .

Diagnostic utility of @entity57431 immunohistochemistry in differentiating cutaneous spread of mantle cell lymphoma from primary XXXX .

@entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphomas', 'CBCL', 'cutaneous B-cell lymphoma'] @entity4910 :: ('595', 'Gene') :: ['cyclin D1'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['Mantle cell lymphoma', 'MCL'] @entity57431 :: ('6664', 'Gene') :: ['SOX11']
@entity1892 :: (MESH:D016393,Disease) :: ['cutaneous B-cell lymphomas']
